BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stephens RH, Tanianis-hughes J, Higgs NB, Humphrey M, Warhurst G. Region-Dependent Modulation of Intestinal Permeability by Drug Efflux Transporters: In Vitro Studies in mdr1a(−/−) Mouse Intestine. J Pharmacol Exp Ther 2002;303:1095-101. [DOI: 10.1124/jpet.102.041236] [Cited by in Crossref: 76] [Cited by in F6Publishing: 76] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Sultan AA, El Nashar NF, Ashmawy SM, El Maghraby GM. Cubosomes for Enhancing Intestinal Absorption of Fexofenadine Hydrochloride: In situ and in vivo Investigation. Int J Nanomedicine 2022;17:3543-60. [PMID: 35983479 DOI: 10.2147/IJN.S370235] [Reference Citation Analysis]
2 Ntamo Y, Jack B, Ziqubu K, Mazibuko-Mbeje SE, Nkambule BB, Nyambuya TM, Mabhida SE, Hanser S, Orlando P, Tiano L, Dludla PV. Epigallocatechin gallate as a nutraceutical to potentially target the metabolic syndrome: novel insights into therapeutic effects beyond its antioxidant and anti-inflammatory properties. Crit Rev Food Sci Nutr 2022;:1-23. [PMID: 35916835 DOI: 10.1080/10408398.2022.2104805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Fayed ND, Arafa MF, Essa EA, El Maghraby GM. Lopinavir-menthol co-crystals for enhanced dissolution rate and intestinal absorption. J Drug Deliv Sci Technol 2022;74:103587. [PMID: 35845293 DOI: 10.1016/j.jddst.2022.103587] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Mohsen NM, El-din EEZ, Osman MA, Ashmawy SM. Investigation of the effect of verapamil on the regional absorption of sofosbuvir from rabbit intestine in situ. DARU J Pharm Sci 2022;30:49-58. [DOI: 10.1007/s40199-021-00429-1] [Reference Citation Analysis]
5 Liu X. ABC Family Transporters. Adv Exp Med Biol 2019;1141:13-100. [PMID: 31571164 DOI: 10.1007/978-981-13-7647-4_2] [Cited by in Crossref: 88] [Cited by in F6Publishing: 30] [Article Influence: 29.3] [Reference Citation Analysis]
6 Stevens LJ, van Lipzig MMH, Erpelinck SLA, Pronk A, van Gorp J, Wortelboer HM, van de Steeg E. A higher throughput and physiologically relevant two-compartmental human ex vivo intestinal tissue system for studying gastrointestinal processes. Eur J Pharm Sci 2019;137:104989. [PMID: 31301485 DOI: 10.1016/j.ejps.2019.104989] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
7 Xue Y, Ma C, Hanna I, Pan G. Intestinal Transporter-Associated Drug Absorption and Toxicity. Advances in Experimental Medicine and Biology 2019. [DOI: 10.1007/978-981-13-7647-4_8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
8 Ashmawy SM, El-Gizawy SA, El Maghraby GM, Osman MA. Regional difference in intestinal drug absorption as a measure for the potential effect of P-glycoprotein efflux transporters. J Pharm Pharmacol 2019;71:362-70. [PMID: 30362574 DOI: 10.1111/jphp.13036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
9 Dou L, Mai Y, Madla CM, Orlu M, Basit AW. P-glycoprotein expression in the gastrointestinal tract of male and female rats is influenced differently by food. European Journal of Pharmaceutical Sciences 2018;123:569-75. [DOI: 10.1016/j.ejps.2018.08.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
10 Domínguez-Avila JA, Wall-Medrano A, Velderrain-Rodríguez GR, Chen CO, Salazar-López NJ, Robles-Sánchez M, González-Aguilar GA. Gastrointestinal interactions, absorption, splanchnic metabolism and pharmacokinetics of orally ingested phenolic compounds. Food Funct 2017;8:15-38. [PMID: 28074953 DOI: 10.1039/c6fo01475e] [Cited by in Crossref: 103] [Cited by in F6Publishing: 107] [Article Influence: 25.8] [Reference Citation Analysis]
11 Ye JH, Augustin MA. Nano- and micro-particles for delivery of catechins: Physical and biological performance. Crit Rev Food Sci Nutr 2019;59:1563-79. [PMID: 29345975 DOI: 10.1080/10408398.2017.1422110] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 9.3] [Reference Citation Analysis]
12 Kojovic D, Piquette-miller M. Regulation of Drug Transporters by Inflammation. Drug Metabolism in Diseases. Elsevier; 2017. pp. 59-89. [DOI: 10.1016/b978-0-12-802949-7.00003-1] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
13 Sun L, Sun J, He Z. Exploring the Feasibility of Biowaiver Extension of BCS Class III Drugs with Site-Specific Absorption Using Gastrointestinal Simulation Technology. Eur J Drug Metab Pharmacokinet 2017;42:471-87. [DOI: 10.1007/s13318-016-0361-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
14 Akazawa T, Uchida Y, Tachikawa M, Ohtsuki S, Terasaki T. Quantitative Targeted Absolute Proteomics of Transporters and Pharmacoproteomics-Based Reconstruction of P-Glycoprotein Function in Mouse Small Intestine. Mol Pharmaceutics 2016;13:2443-56. [DOI: 10.1021/acs.molpharmaceut.6b00196] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
15 Hubbard D, Bond T, Ghandehari H. Regional Morphology and Transport of PAMAM Dendrimers Across Isolated Rat Intestinal Tissue. Macromol Biosci 2015;15:1735-43. [PMID: 26332343 DOI: 10.1002/mabi.201500225] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
16 Zheng Y, Benet LZ, Okochi H, Chen X. pH Dependent but not P-gp Dependent Bidirectional Transport Study of S-propranolol: The Importance of Passive Diffusion. Pharm Res 2015;32:2516-26. [PMID: 25690341 DOI: 10.1007/s11095-015-1640-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
17 Cressman AM, Petrovic V, Piquette-miller M. Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response. Expert Review of Clinical Pharmacology 2014;5:69-89. [DOI: 10.1586/ecp.11.66] [Cited by in Crossref: 68] [Cited by in F6Publishing: 69] [Article Influence: 8.5] [Reference Citation Analysis]
18 Yano K, Tomono T, Sakai R, Kano T, Morimoto K, Kato Y, Ogihara T. Contribution of Radixin to P-Glycoprotein Expression and Transport Activity in Mouse Small Intestine In Vivo. Journal of Pharmaceutical Sciences 2013;102:2875-81. [DOI: 10.1002/jps.23637] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
19 Zwart LLD, Monbaliu JG, Annaert PP. Absorption, Distribution, Metabolism and Excretion (ADME) and Pharmacokinetic Assessments in Juvenile Animals. Pediatric Drug Development 2013. [DOI: 10.1002/9781118312087.ch20] [Reference Citation Analysis]
20 Su L, Dong L, Bughio S, Guo M, Wang L. Effect of colibacillosis or coccidiosis on expression of breast cancer resistance protein in small intestine and liver of chickens. J Vet Pharmacol Ther 2014;37:53-8. [DOI: 10.1111/jvp.12051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
21 Lai Y. Transporter study methodologies. Transporters in Drug Discovery and Development 2013. [DOI: 10.1533/9781908818287.675] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
22 Lai Y. Drug transporters in drug discovery and development. Transporters in Drug Discovery and Development. Elsevier; 2013. pp. 633-74. [DOI: 10.1533/9781908818287.633] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
23 Trivedi R, Redente EF, Thakur A, Riches DW, Kompella UB. Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice. Nanotechnology 2012;23:505101. [PMID: 23186914 DOI: 10.1088/0957-4484/23/50/505101] [Cited by in Crossref: 56] [Cited by in F6Publishing: 62] [Article Influence: 5.6] [Reference Citation Analysis]
24 Togawa N, Miyaji T, Izawa S, Omote H, Moriyama Y. A Na + -phosphate cotransporter homologue (SLC17A4 protein) is an intestinal organic anion exporter. American Journal of Physiology-Cell Physiology 2012;302:C1652-60. [DOI: 10.1152/ajpcell.00015.2012] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
25 Haslam IS, Wright JA, O'Reilly DA, Sherlock DJ, Coleman T, Simmons NL. Intestinal ciprofloxacin efflux: the role of breast cancer resistance protein (ABCG2). Drug Metab Dispos 2011;39:2321-8. [PMID: 21930826 DOI: 10.1124/dmd.111.038323] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 3.7] [Reference Citation Analysis]
26 Dube A, Nicolazzo JA, Larson I. Chitosan nanoparticles enhance the plasma exposure of (-)-epigallocatechin gallate in mice through an enhancement in intestinal stability. Eur J Pharm Sci 2011;44:422-6. [PMID: 21925598 DOI: 10.1016/j.ejps.2011.09.004] [Cited by in Crossref: 101] [Cited by in F6Publishing: 106] [Article Influence: 9.2] [Reference Citation Analysis]
27 Ovadia O, Greenberg S, Chatterjee J, Laufer B, Opperer F, Kessler H, Gilon C, Hoffman A. The effect of multiple N-methylation on intestinal permeability of cyclic hexapeptides. Mol Pharm 2011;8:479-87. [PMID: 21375270 DOI: 10.1021/mp1003306] [Cited by in Crossref: 120] [Cited by in F6Publishing: 119] [Article Influence: 10.9] [Reference Citation Analysis]
28 Sutton SC, Smith PL. Animal Model Systems Suitable for Controlled Release Modeling. Controlled Release in Oral Drug Delivery 2011. [DOI: 10.1007/978-1-4614-1004-1_4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
29 Dube A, Nicolazzo JA, Larson I. Chitosan nanoparticles enhance the intestinal absorption of the green tea catechins (+)-catechin and (-)-epigallocatechin gallate. Eur J Pharm Sci. 2010;41:219-225. [PMID: 20600878 DOI: 10.1016/j.ejps.2010.06.010] [Cited by in Crossref: 189] [Cited by in F6Publishing: 165] [Article Influence: 15.8] [Reference Citation Analysis]
30 Lowes S, Haslam IS, Fihn BM, Hilgendorf C, Karlsson JE, Simmons NL, Ungell AL. The Effects of Pregnenolone 16α-Carbonitrile Dosing on Digoxin Pharmacokinetics and Intestinal Absorption in the Rat. Pharmaceutics 2010;2:61-77. [PMID: 27721343 DOI: 10.3390/pharmaceutics2010061] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
31 Kiki-Mvouaka S, Ménez C, Borin C, Lyazrhi F, Foucaud-Vignault M, Dupuy J, Collet X, Alvinerie M, Lespine A. Role of P-glycoprotein in the disposition of macrocyclic lactones: A comparison between ivermectin, eprinomectin, and moxidectin in mice. Drug Metab Dispos 2010;38:573-80. [PMID: 20089736 DOI: 10.1124/dmd.109.030700] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 4.1] [Reference Citation Analysis]
32 Chen L, Yang J, Davey AK, Chen Y, Wang J, Liu X. Effects of diammonium glycyrrhizinate on the pharmacokinetics of aconitine in rats and the potential mechanism. Xenobiotica 2009;39:955-63. [DOI: 10.3109/00498250903271997] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 4.8] [Reference Citation Analysis]
33 Dahan A, Sabit H, Amidon GL. The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J 2009;11:205-13. [PMID: 19319690 DOI: 10.1208/s12248-009-9092-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
34 Dahan A, Amidon GL. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs. Mol Pharm. 2009;6:19-28. [PMID: 19248230 DOI: 10.1021/mp800088f] [Cited by in Crossref: 122] [Cited by in F6Publishing: 123] [Article Influence: 9.4] [Reference Citation Analysis]
35 Murakami Y, Higashi Y, Matsunaga N, Koyanagi S, Ohdo S. Circadian clock-controlled intestinal expression of the multidrug-resistance gene mdr1a in mice. Gastroenterology 2008;135:1636-1644.e3. [PMID: 18773899 DOI: 10.1053/j.gastro.2008.07.073] [Cited by in Crossref: 82] [Cited by in F6Publishing: 91] [Article Influence: 5.9] [Reference Citation Analysis]
36 Anderle P, Nielsen CU. Transporters in the Gastrointestinal Tract. Methods and Principles in Medicinal Chemistry 2008. [DOI: 10.1002/9783527623860.ch10] [Reference Citation Analysis]
37 Haritova AM, Rusenova NV, Rusenov AG, Schrickx J, Lashev LD, Fink-gremmels J. Effects of fluoroquinolone treatment on MDR1 and MRP2 mRNA expression in Escherichia coli -infected chickens. Avian Pathology 2008;37:465-70. [DOI: 10.1080/03079450802272945] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
38 Woollard HF, Billingham J, Jensen OE, Lian G. A multi-scale model for solute transport in a wavy-walled channel. J Eng Math 2009;64:25-48. [DOI: 10.1007/s10665-008-9239-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
39 Collett A, Higgs NB, Gironella M, Zeef LA, Hayes A, Salmo E, Haboubi N, Iovanna JL, Carlson GL, Warhurst G. Early molecular and functional changes in colonic epithelium that precede increased gut permeability during colitis development in mdr1a(-/-) mice. Inflamm Bowel Dis. 2008;14:620-631. [PMID: 18275070 DOI: 10.1002/ibd.20375] [Cited by in Crossref: 37] [Cited by in F6Publishing: 43] [Article Influence: 2.6] [Reference Citation Analysis]
40 Haritova AM, Schrickx J, Lashev LD, Fink-gremmels J. Expression of MDR1, MRP2 and BCRP mRNA in tissues of turkeys. Journal of Veterinary Pharmacology and Therapeutics 2008;31:378-85. [DOI: 10.1111/j.1365-2885.2008.00968.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
41 Nishimura T, Kato Y, Amano N, Ono M, Kubo Y, Kimura Y, Fujita H, Tsuji A. Species Difference in Intestinal Absorption Mechanism of Etoposide and Digoxin between Cynomolgus Monkey and Rat. Pharm Res 2008;25:2467-76. [DOI: 10.1007/s11095-008-9658-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
42 MacLean C, Moenning U, Reichel A, Fricker G. Closing the gaps: a full scan of the intestinal expression of p-glycoprotein, breast cancer resistance protein, and multidrug resistance-associated protein 2 in male and female rats. Drug Metab Dispos. 2008;36:1249-1254. [PMID: 18378562 DOI: 10.1124/dmd.108.020859] [Cited by in Crossref: 113] [Cited by in F6Publishing: 118] [Article Influence: 8.1] [Reference Citation Analysis]
43 Lennernäs H. Intestinal permeability and its relevance for absorption and elimination. Xenobiotica 2007;37:1015-51. [PMID: 17968735 DOI: 10.1080/00498250701704819] [Cited by in Crossref: 201] [Cited by in F6Publishing: 167] [Article Influence: 14.4] [Reference Citation Analysis]
44 Katneni K, Charman SA, Porter CJ. Use of plasma proteins as solubilizing agents in in vitro permeability experiments: Correction for unbound drug concentration using the reciprocal permeability approach. Journal of Pharmaceutical Sciences 2008;97:209-24. [DOI: 10.1002/jps.20877] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
45 Collett A, Stephens RH, Harwood MD, Humphrey M, Dallman L, Bennett J, Davis J, Carlson GL, Warhurst G. Investigation of Regional Mechanisms Responsible for Poor Oral Absorption in Humans of a Modified Release Preparation of the α-Adrenoreceptor Antagonist, 4-Amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4 tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline (UK-338,003): The Rational Use of ex Vivo Intestine to Predict in Vivo Absorption. Drug Metab Dispos 2007;36:87-94. [DOI: 10.1124/dmd.107.016865] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
46 Ballent M, Lifschitz A, Virkel G, Sallovitz J, Lanusse C. Involvement of P-glycoprotein on ivermectin kinetic behaviour in sheep: itraconazole-mediated changes on gastrointestinal disposition. J Vet Pharmacol Ther 2007;30:242-8. [DOI: 10.1111/j.1365-2885.2007.00848.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 2.3] [Reference Citation Analysis]
47 Lohner K, Schnäbele K, Daniel H, Oesterle D, Rechkemmer G, Göttlicher M, Wenzel U. Flavonoids alter P-gp expression in intestinal epithelial cells in vitro and in vivo. Mol Nutr Food Res 2007;51:293-300. [DOI: 10.1002/mnfr.200600225] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.3] [Reference Citation Analysis]
48 Berggren S, Gall C, Wollnitz N, Ekelund M, Karlbom U, Hoogstraate J, Schrenk D, Lennernäs H. Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol Pharm. 2007;4:252-257. [PMID: 17263554 DOI: 10.1021/mp0600687] [Cited by in Crossref: 147] [Cited by in F6Publishing: 154] [Article Influence: 9.8] [Reference Citation Analysis]
49 Schmitz JM, McCracken VJ, Dimmitt RA, Lorenz RG. Expression of CXCL15 (Lungkine) in murine gastrointestinal, urogenital, and endocrine organs. J Histochem Cytochem 2007;55:515-24. [PMID: 17242461 DOI: 10.1369/jhc.6A7121.2007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
50 Varma MV, Perumal OP, Panchagnula R. Functional role of P-glycoprotein in limiting peroral drug absorption: optimizing drug delivery. Current Opinion in Chemical Biology 2006;10:367-73. [DOI: 10.1016/j.cbpa.2006.06.015] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
51 Yao HM, Chiou WL. The complexity of intestinal absorption and exsorption of digoxin in rats. Int J Pharm 2006;322:79-86. [PMID: 16781832 DOI: 10.1016/j.ijpharm.2006.05.030] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
52 Englund G, Rorsman F, Rönnblom A, Karlbom U, Lazorova L, Gråsjö J, Kindmark A, Artursson P. Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur J Pharm Sci 2006;29:269-77. [PMID: 16822659 DOI: 10.1016/j.ejps.2006.04.010] [Cited by in Crossref: 272] [Cited by in F6Publishing: 230] [Article Influence: 17.0] [Reference Citation Analysis]
53 Ballent M, Lifschitz A, Virkel G, Sallovitz J, Lanusse C. MODULATION OF THE P-GLYCOPROTEIN-MEDIATED INTESTINAL SECRETION OF IVERMECTIN: IN VITRO AND IN VIVO ASSESSMENTS. Drug Metab Dispos 2006;34:457-63. [DOI: 10.1124/dmd.105.007757] [Cited by in Crossref: 68] [Cited by in F6Publishing: 68] [Article Influence: 4.0] [Reference Citation Analysis]
54 Yazaki K. ABC transporters involved in the transport of plant secondary metabolites. FEBS Letters 2006;580:1183-91. [DOI: 10.1016/j.febslet.2005.12.009] [Cited by in Crossref: 260] [Cited by in F6Publishing: 208] [Article Influence: 15.3] [Reference Citation Analysis]
55 Varma MV, Panchagnula R. pH-dependent functional activity of P-glycoprotein in limiting intestinal absorption of protic drugs: Kinetic analysis of quinidine efflux in situ. Journal of Pharmaceutical Sciences 2005;94:2632-43. [DOI: 10.1002/jps.20489] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
56 Elson CO, Cong Y, McCracken VJ, Dimmitt RA, Lorenz RG, Weaver CT. Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol Rev. 2005;206:260-276. [PMID: 16048554 DOI: 10.1111/j.0105-2896.2005.00291.x] [Cited by in Crossref: 370] [Cited by in F6Publishing: 394] [Article Influence: 21.8] [Reference Citation Analysis]
57 Mehuys E, Remon J, Korst A, Van Bortel L, Mols R, Augustijns P, Porter C, Vervaet C. Human bioavailability of propranolol from a matrix-in-cylinder system with a HPMC-Gelucire® core. Journal of Controlled Release 2005;107:523-36. [DOI: 10.1016/j.jconrel.2005.06.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
58 Thörn M, Finnström N, Lundgren S, Rane A, Lööf L. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol 2005;60:54-60. [PMID: 15963094 DOI: 10.1111/j.1365-2125.2005.02389.x] [Cited by in Crossref: 144] [Cited by in F6Publishing: 147] [Article Influence: 8.5] [Reference Citation Analysis]
59 Fearn RA, Hirst BH. Predicting oral drug absorption and hepatobiliary clearance: Human intestinal and hepatic in vitro cell models. Environ Toxicol Pharmacol 2006;21:168-78. [PMID: 21783654 DOI: 10.1016/j.etap.2005.06.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 1.7] [Reference Citation Analysis]
60 Varma MV, Panchagnula R. Prediction of in vivo intestinal absorption enhancement on P-glycoprotein inhibition, from rat in situ permeability. Journal of Pharmaceutical Sciences 2005;94:1694-704. [DOI: 10.1002/jps.20309] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 3.8] [Reference Citation Analysis]
61 Kandimalla KK, Donovan MD. Localization and Differential Activity of P-glycoprotein in the Bovine Olfactory and Nasal Respiratory Mucosae. Pharm Res 2005;22:1121-8. [DOI: 10.1007/s11095-005-5420-3] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 2.2] [Reference Citation Analysis]
62 Buyse M, Radeva G, Bado A, Farinotti R. Intestinal inflammation induces adaptation of P-glycoprotein expression and activity. Biochem Pharmacol 2005;69:1745-54. [PMID: 15885661 DOI: 10.1016/j.bcp.2005.03.025] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 1.8] [Reference Citation Analysis]
63 Cao X, Yu LX, Barbaciru C, Landowski CP, Shin H, Gibbs S, Miller HA, Amidon GL, Sun D. Permeability Dominates in Vivo Intestinal Absorption of P-gp Substrate with High Solubility and High Permeability. Mol Pharmaceutics 2005;2:329-40. [DOI: 10.1021/mp0499104] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 3.5] [Reference Citation Analysis]
64 Weitschies W, Bernsdorf A, Giessmann T, Zschiesche M, Modess C, Hartmann V, Mrazek C, Wegner D, Nagel S, Siegmund W. The Talinolol Double-Peak Phenomenon Is Likely Caused by Presystemic Processing After Uptake from Gut Lumen. Pharm Res 2005;22:728-35. [DOI: 10.1007/s11095-005-2588-5] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 3.1] [Reference Citation Analysis]
65 Lacombe O, Woodley J, Solleux C, Delbos J, Boursier-neyret C, Houin G. Localisation of drug permeability along the rat small intestine, using markers of the paracellular, transcellular and some transporter routes. European Journal of Pharmaceutical Sciences 2004;23:385-91. [DOI: 10.1016/j.ejps.2004.09.002] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 2.3] [Reference Citation Analysis]
66 Collett A, Tanianis-Hughes J, Warhurst G. Rapid induction of P-glycoprotein expression by high permeability compounds in colonic cells in vitro: a possible source of transporter mediated drug interactions? Biochem Pharmacol 2004;68:783-90. [PMID: 15276086 DOI: 10.1016/j.bcp.2004.05.006] [Cited by in Crossref: 57] [Cited by in F6Publishing: 59] [Article Influence: 3.2] [Reference Citation Analysis]
67 Cornaire G, Woodley J, Hermann P, Cloarec A, Arellano C, Houin G. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. International Journal of Pharmaceutics 2004;278:119-31. [DOI: 10.1016/j.ijpharm.2004.03.001] [Cited by in Crossref: 229] [Cited by in F6Publishing: 214] [Article Influence: 12.7] [Reference Citation Analysis]
68 Unadkat J, Wei X. Drug Transporters. Drugs and the Pharmaceutical Sciences 2004. [DOI: 10.1201/9780203026427.ch6] [Reference Citation Analysis]
69 Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist. 2003;8:411-424. [PMID: 14530494 DOI: 10.1634/theoncologist.8-5-411] [Cited by in Crossref: 550] [Cited by in F6Publishing: 577] [Article Influence: 30.6] [Reference Citation Analysis]
70 Ward KW, Stelman GJ, Morgan JA, Zeigler KS, Azzarano LM, Kehler JR, Mcsurdy-freed JE, Proksch JW, Smith BR. DEVELOPMENT OF AN IN VIVO PRECLINICAL SCREEN MODEL TO ESTIMATE ABSORPTION AND FIRST-PASS HEPATIC EXTRACTION OF XENOBIOTICS. II. USE OF KETOCONAZOLE TO IDENTIFY P-GLYCOPROTEIN/CYP3A-LIMITED BIOAVAILABILITY IN THE MONKEY. Drug Metab Dispos 2004;32:172-7. [DOI: 10.1124/dmd.32.2.172] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 2.3] [Reference Citation Analysis]
71 Takara K, Ohnishi N, Horibe S, Yokoyama T. EXPRESSION PROFILES OF DRUG-METABOLIZING ENZYME CYP3A AND DRUG EFFLUX TRANSPORTER MULTIDRUG RESISTANCE 1 SUBFAMILY mRNAS IN RAT SMALL INTESTINE. Drug Metab Dispos 2003;31:1235-9. [DOI: 10.1124/dmd.31.10.1235] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 3.2] [Reference Citation Analysis]